CNP0456830

CNP0456830 is a natural product compound identified from the COCONUT (COmmon COmponents of NATural products) database as a potential dual-target inhibitor for the treatment of lung adenocarcinoma. Research presented at the 2025 World Conference on Lung Cancer (WCLC) utilized machine learning models and molecular dynamics simulations to screen inhibitors, identifying CNP0456830 as a promising candidate due to its stable binding and low free energy interactions with both the epidermal growth factor receptor (EGFR) and the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). By targeting these two key signaling pathways simultaneously, the compound is designed to overcome resistance mechanisms often encountered with single-target therapies in lung cancer.